Showing 26–39 of 39 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Molly F. Franke, ScD
…nostic tool that can help clinicians make a microbiological diagnosis in children who present with signs and symptoms suggestive of TB. Specific aim 1: To identify the types of patient samples from which to best detect Mtb DNA in children with TB. We propose to obtain serial sam…
Hospital Mutua de Terrassa
In countries with a low incidence of Tuberculosis (TB), the incidence remains higher among the immigrant population than among the autochthonous population beyond the first years after arrival in the host country. In addition, at a pediatric level, most cases are produced in immi…
John Metcalfe, MD, PhD, MPH
…th standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB). This study compared a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB). Rando…
Michael Marmor
To determine the incidence of tuberculosis in an inner city population, identify risk factors for TB, describe the natural history in adults and children, evaluate the effect of Mycobacterium tuberculosis (Mtb) co-infection on the progression of human immunodeficiency virus disea…
Dr Govind K Makharia, MD, DM, DNB
Most of the guidelines on the treatment of tuberculosis suggest that 6 months treatment is sufficient for extrapulmonary tuberculosis except for bone tuberculosis and tubercular meningitis. Despite these recommendations, most physicians treating abdominal tuberculosis use antitub…
Anneke Hesseling, M.D., Ph.D.
…diagnosed or bacteriologically confirmed rifampin-resistant tuberculosis (RR-TB). The study was designed to evaluate the PK, safety, and tolerability of BDQ over 24 weeks. The purpose of this study was to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquilin…
Andrew Colin, MD, SM, Shatha Yousef, MD
…evalence of nontuberculous mycobacterial infection (NTM) in pediatric patients with cystic fibrosis in the State fo Florida. HYPOTHESIS: There is high prevalence of NTM in CF pediatric population in the State of Florida, and likely higher than in the rest of the country. Non-tub…
International Centre for Diarrhoeal Disease Research, Bangladesh
…ort study is to learn about the long-term health effects of tuberculosis (TB) in children, adolescents, and adults who have completed standard TB treatment in Bangladesh. The study aims to track the evolution of pulmonary and cardiac sequelae within the first two years after TB t…
Helen M McIlleron, PhD, Heather Zar, PhD
… to: 1. To evaluate the pharmacokinetics of first line antituberculosis drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) when applying the 2010 WHO/IUATLD dosing guidelines across pediatric populations (0-12 years of age, HIV infected and uninfected, and with varied nu…
Boris Tchounga, MD, PHD, Daniel Atwine, MD, PhD
The many gaps observed in the cascade of care of tuberculosis (TB) child contacts occur mostly in the screening, preventive therapy (PT) initiation and PT completion steps and the main drivers of these gaps are considered to be the health system infrastructure, limited worker res…
Francesca M Conradie
BEAT Tuberculosis is a phase 3, open label, multi-centre, randomized controlled trial. The purpose of this trial is to compare the efficacy and safety of a Study Strategy consisting of 6 months of bedaquiline (BDQ), delamanid (DLM), and linezolid (LNZ), with levofloxacin (LVX) an…
Jyoti S. Mathad, MD, MSc
… HIV-1-uninfected pregnant and postpartum women with latent tuberculosis (TB). TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at higher risk of developing active TB. This study evaluated the pharmacokinetic…
Gonzalo G Alvarez, MD
… current standard of 9 months INH. The treatment of latent tuberculosis infection (LTBI) is a vital component of the overall strategy to reduce TB in a population. Treatment prevents ongoing transmission in communities by preventing the development of active TB disease. The curr…
Holly Rawizza, MD, MPH
Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics of newer HIV/TB cotreatment strategies in children. Current WHO-recommended rifampicin dosages result in low concentrations in most children, and h…